Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Beam Therapeutics ( (BEAM) ) just unveiled an update.
On March 2, 2026, Beam Therapeutics Inc. and Japan-based Bio Palette Co., Ltd. mutually terminated their 2019 cross-license agreement covering base-editing and gene-editing patents, in connection with the planned dissolution of Bio Palette. Under the original deal, Beam held an exclusive, royalty-bearing license to exploit certain Bio Palette base-editing patents for human disease treatments globally, excluding microbiome products in Asia, while granting Bio Palette exclusive rights to use certain Beam patents in the Asian microbiome field.
Ahead of Beam’s termination agreement with Bio Palette, Bio Palette and Kobe University ended their own 2017 license, triggering a standby license that Kobe had pre-arranged directly with Beam on February 9, 2026. As a result, Beam now holds an exclusive license from Kobe, of the same scope as its prior license, to practice key base-editing patents originally accessed through Bio Palette, with all mutual rights and payment obligations between Beam and Bio Palette under the terminated agreements fully released going forward.
The most recent analyst rating on (BEAM) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.
Spark’s Take on BEAM Stock
According to Spark, TipRanks’ AI Analyst, BEAM is a Neutral.
BEAM’s score reflects a strong balance sheet and positive, well-defined pipeline/financing updates from the latest earnings call, supported by constructive technical momentum. These positives are tempered by very weak current operating fundamentals (large losses and heavy cash burn) and limited support from traditional valuation metrics given negative earnings.
To see Spark’s full report on BEAM stock, click here.
More about Beam Therapeutics
Beam Therapeutics Inc. is a biotechnology company focused on developing treatments for human disease using base-editing and gene-editing technologies. The company’s licensing arrangements have given it access to key patent rights in these areas to support the development and commercialization of therapeutic products worldwide, with certain historical exclusions in the microbiome field in Asia.
Average Trading Volume: 1,808,058
Technical Sentiment Signal: Buy
Current Market Cap: $2.77B
For detailed information about BEAM stock, go to TipRanks’ Stock Analysis page.